About 0.8 million people die because of hepatitis B virus (HBV) infection each year. In
around 5% of infected adults, the immune system is ineffective in countering HBV infection …

Objectives Dissecting the underlying mechanism of T cells remodeling mediated by
interferon α (IFN-α) is indispensable for achieving an optimum therapeutic response in …

Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is
the causative agent of acute and chronic hepatitis. HBV can resist immune system …

Interferon alpha (IFNα) is commonly used for the treatment of chronic hepatitis B (CHB)
patients. There are 13 different IFNα subtypes in humans, but only the subtype IFNα2 is used …

Chronic hepatitis B virus (HBV) infection continues to be a major health problem worldwide
and remains hard to be cured. Therapy with interferon (IFN) α is an important method for the …

Chronic hepatitis B virus (HBV) infection remains a major health burden worldwide for which
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …

Chronic hepatitis B virus (HBV) infection imposes a severe burden on global public health.
Currently, there are no curative therapies for millions of chronic HBV-infected patients …

Abstract Type I interferon (IFN‐I) is constitutively produced in the bone marrow (BM), and
induced at sites of inflammation and following infection by viruses or microorganisms. We …

Interferons α and β (IFNα and IFNβ) are type I interferons produced by the host to control
pathogen propagation. However, only a minority of chronic hepatitis B (CHB) patients …

Although not directly cytopathic, hepatitis B and C viruses (HBV and HCV) are responsible
for millions of deaths per year, and the aging patient population presents a severe public …